HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lean, M. E.J. Articles by Pajonk, F.-G. Search for Related Content PubMed PubMed Citation Articles by Lean, M. E.J. Articles by Pajonk, F.-G. Social Bookmarking                What's this?

Patients on Atypical Antipsychotic Drugs

Another high-risk group for type 2 diabetes

¹ Department of Human Nutrition, University of Glasgow, Glasgow, U.K
² Department of Psychiatry and Psychotherapy, the Saarland University Hospital, Homburg, Germany

Patients with schizophrenia are more likely than the general population to develop diabetes, which contributes to a high risk of cardiovascular complications; individuals with schizophrenia are two to three times more likely to die from cardiovascular disease than the general population. The risk of diabetes, and hence cardiovascular disease, is particularly increased by some of the new atypical antipsychotic drugs. Individuals taking an atypical antipsychotic drug, particularly younger patients under 40 years of age (odds ratio 1.63, 95% CI 1.23–2.16), represent an underrecognized group at high risk of type 2 diabetes. The mechanisms responsible for antipsychotic-induced diabetes remain unclear. Hypotheses include these drugs’ potential to cause weight gain, possibly through antagonism at the H₁, 5-HT_2A, or 5-HT_2C receptors. Other mechanisms independent of weight gain lead to elevation of serum leptin and insulin resistance. Patients with psychoses have difficulties with diet and lifestyle interventions for diabetes and weight management. If hyperglycemia develops, withdrawal from antipsychotic medication will often be inappropriate, and a change to an atypical antipsychotic drug with lower diabetogenic potential should be considered, especially in younger patients. Management of psychoses should routinely include body weight and blood glucose monitoring and steps to promote exercise and minimize weight gain. Careful collaboration between the psychiatric and diabetology teams is essential to minimize the risk of diabetes in patients taking atypical antipsychotic medication and for effective management when it develops. This collaboration will also help minimize the already high risk of cardiovascular disease in individuals with schizophrenia.

Abbreviations: EPS, extrapyramidal side effect • FDA, Food and Drug Administration

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Weber, M. Colon, and M. Nelson Pilot Study of a Cognitive Behavioral Group Intervention to Prevent Further Weight Gain in Hispanic Individuals With Schizophrenia Journal of the American Psychiatric Nurses Association, January 1, 2008; 13(6): 353 - 359. [Abstract] [PDF]

				W.S. Leslie, C.R. Hankey, and M.E.J. Lean Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review QJM, July 1, 2007; 100(7): 395 - 404. [Abstract] [Full Text] [PDF]

				M. De Hert, L. Hanssens, R. van Winkel, M. Wampers, D. Van Eyck, A. Scheen, and J. Peuskens A Case Series: Evaluation of the Metabolic Safety of Aripiprazole Schizophr Bull, May 1, 2007; 33(3): 823 - 830. [Abstract] [Full Text] [PDF]

				M. Shastri, L. Alla, and M. Sabaratnam Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series J Psychopharmacol, November 1, 2006; 20(6): 863 - 867. [Abstract] [PDF]

				M. Malone Medications Associated with Weight Gain Ann. Pharmacother., December 1, 2005; 39(12): 2046 - 2054. [Abstract] [Full Text] [PDF]

				A. Mohl, K. Westlye, S. Opjordsmoen, A. Lex, A. Schreiner, M. Benoit, P. Braunig, and R. Medori Long-acting risperidone in stable patients with schizoaffective disorder J Psychopharmacol, September 1, 2005; 19(5_suppl): 22 - 31. [Abstract] [PDF]

				M. Malone, S. A Alger-Mayer, and D. A Anderson Medication Associated with Weight Gain May Influence Outcome in a Weight Management Program Ann. Pharmacother., July 1, 2005; 39(7): 1204 - 1208. [Abstract] [Full Text] [PDF]

				D. E. Johnson, H. Yamazaki, K. M. Ward, A. W. Schmidt, W. S. Lebel, J. L. Treadway, E. M. Gibbs, W. S. Zawalich, and H. Rollema Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion From Perifused Rat Islets: Role of Muscarinic Antagonism in Antipsychotic-Induced Diabetes and Hyperglycemia Diabetes, May 1, 2005; 54(5): 1552 - 1558. [Abstract] [Full Text] [PDF]

				C. R. Richardson, G. Faulkner, J. McDevitt, G. S. Skrinar, D. S. Hutchinson, and J. D. Piette Integrating Physical Activity Into Mental Health Services for Persons With Serious Mental Illness Psychiatr Serv, March 1, 2005; 56(3): 324 - 331. [Abstract] [Full Text] [PDF]

				M. E.J. Lean and F.-G. Pajonk Patients on Atypical Antipsychotic Drugs: Another High-Risk Group for Type 2 Diabetes: Response to Hardy and Breier Diabetes Care, November 1, 2003; 26(11): 3202 - 3203. [Full Text] [PDF]

				T. Hardy and A. Breier Patients on Atypical Antipsychotic Drugs: Another High-Risk Group for Type 2 Diabetes: Response to Lean and Pajonk Diabetes Care, November 1, 2003; 26(11): 3200 - 3201. [Full Text] [PDF]